189
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Visual Outcomes of a Second-Generation, Enhanced UV Protected Light Adjustable Lens in Cataract Patients with Previous LASIK and/or PRK

, ORCID Icon, ORCID Icon, ORCID Icon, , , , & show all
Pages 3379-3387 | Received 01 Sep 2023, Accepted 29 Oct 2023, Published online: 06 Nov 2023
 

Abstract

Purpose

To report on the visual outcomes of the second-generation (ActivShieldTM) Light Adjustable Lens (LAL) used in cataract surgery for patients with a history of laser refractive surgery (LASIK and/or photorefractive keratectomy [PRK]) using a co-managed, open-access methodology.

Patients and Methods

This retrospective case series of consecutive patients with history of laser refractive surgery implanted with the second-generation LAL with an emmetropic target were included in the study. Following surgery, all patients received their ultraviolet (UV) light treatments at a separate open-access facility through a co-managed arrangement. Uncorrected distance visual acuity (UDVA), spherical equivalent (SE), and residual cylinder for eyes with an emmetropic refractive target were the primary outcome measures as documented at the patient’s final, stable, refractive postoperative exam.

Results

Thirty-three patients (34 eyes) with a history of laser refractive surgery were included in the study and implanted with the second-generation LAL with a postoperative emmetropic refractive target. Twenty-eight (82.4%) saw 20/20 or better and 9 (26.5%) saw 20/15 or better. The mean SE was 0.01 ± 0.31 D and 33 (97.1%) were within ±0.50 D SE of plano. The mean residual cylinder was −0.28 ± 0.32 D and 30 (88.2%) were within ±0.50 D.

Conclusion

Use of the second-generation LAL was efficacious in cataract surgical patients with a history of LASIK and/or PRK using a co-managed, open-access methodology.

Acknowledgments

We thank Hannah Schoenecker for her data collection, organization, and analysis and Terri Flom for providing research guidance.

Disclosure

Jennifer R. Wong, OD is a paid consultant for RxSight.

No other authors report any financial or proprietary interests.

Additional information

Funding

No public or private support was provided for this study.